A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

This study tests a CAR-T cell therapy called DeepTag-GPRC5D, where the patient's immune cells are genetically modified to target and kill multiple myeloma cells (a blood cancer of the bone marrow). This is for patients whose myeloma has returned or is no longer responding to multiple prior treatments. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with multiple myeloma - Your myeloma has failed at least 3 prior treatment regimens, including drugs from three key classes: proteasome inhibitors, immunomodulatory agents, and anti-CD38 antibodies - Your life expectancy is at least 12 weeks - Your blood counts are above minimum required levels - You have good overall health (ECOG 0-2) **You may NOT be eligible if...** - You have a history of brain trauma, seizures, stroke, or significant brain disease - You have serious heart rhythm problems - You are pregnant or breastfeeding - You have HIV or active hepatitis B or C - You recently had other cancer treatments (within 2 weeks) - You had a stem cell transplant within the past 8 weeks - You have another active cancer (except those cured and disease-free for 3+ years) Talk to your doctor to see if this trial is right for you.